Stargardt Disease Pipeline Shows Promising Progress with Emerging Therapies
News related to:DelveInsight Business Research LLP · 2 min read
The Stargardt disease pipeline has shown significant progress in 2026, with the emergence of new gene therapies and novel drug candidates. According to DelveInsight's latest report, the pipeline is a robust space with 20+ active players working to develop a wide range of therapies for this progressive eye disorder.
Belite Bio, Inc. has made a notable breakthrough with the topline results from its global Phase 3 "DRAGON" trial evaluating Tinlarebant. This novel oral therapy is intended to reduce the accumulation of vitamin A-based toxins (bisretinoids) that contribute to retinal disease in Stargardt disease type 1 (STGD1). Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the US, Europe, and Japan for the treatment of STGD1. The drug is currently in the Phase III stage of its clinical trial.
Kiora Pharmaceuticals is also making strides with KIO-301, a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). This therapy targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. KIO-301 is currently in the Phase II stage of clinical trials.
Ocugen is developing OCU410, which utilizes an AAV delivery platform for the retinal delivery of the RORA gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress. This therapy is currently in the Phase I/II stage of clinical trials.
Other promising therapies in the pipeline include Emixustat, OCU410ST, SB-007, STG-001, ALK-001, ACDN-01, and VG801. These drugs are at various stages of development, from preclinical to Phase III trials.
The report also highlights the involvement of several key companies in the Stargardt disease pipeline, including Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, and Splice Bio. These companies are involved in targeted therapeutics development with respective active and inactive projects.
DelveInsight's report provides a detailed analysis of the Stargardt disease pipeline, covering various aspects such as the route of administration, target receptor, monotherapy or combination therapy, and molecular type. The report categorizes products under oral, intravenous, subcutaneous, parenteral, and topical routes of administration. Additionally, it segments products based on their molecule types, including recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies.
The report also addresses the unmet needs in the Stargardt disease market, market drivers, and barriers, providing a comprehensive view of the future perspectives and analyst views. It covers the therapeutic assessment of the pipeline drugs by product type and clinical stage, offering insights into the late-stage, mid-stage, and early-stage products.
Overall, the Stargardt disease pipeline report provides a detailed and comprehensive analysis of the current landscape and future prospects for this progressive eye disorder. With the promising progress in emerging gene therapies and novel drug candidates, there is hope for significant advancements in the treatment of Stargardt disease in the coming years.